Welcome to BioSeeker Group!

Triple Analysis: Lymphoma, Prostate Cancer and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3460
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lymphoma, Prostate Cancer and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Prostate Cancer and Peptides.

    To find out more about Triple Analysis: Lymphoma, Prostate Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Prostate Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
4SC
7TM Pharma
Abbott
Abiogen
Acceleron Pharma
Active Biotech
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affimed Therapeutics
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
Allostera
Allosterix
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
American Gene Technology International
Amgen
Anavex Life Sciences
Anchor Therapeutics
AndroBioSys
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisense Therapeutics
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Aprea
Apricus Biosciences
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Benitec
Biocon
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
Biolex
BioLineRx
BioMarin
BioNetWorks
BioSante
Biostar
Boehringer Ingelheim
Borean Pharma
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Center of Molecular Immunology
Cephalon
Chemokine Therapeutics
Chiasma
Circadian Technologies
Cleveland BioLabs
Clinuvel
Colby
Compugen
Cornerstone Pharmaceuticals
Cosmo Bioscience
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
Digna Biotech
Dongkook Pharm
Dr Reddy’s
Dynavax Technologies
ECI
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
Ensemble Discovery
EntreMed
Enzon
EpiCept
Epizyme
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Favrille
Ferring
Forma Therapeutics
Formula Pharmaceuticals
Galena Biopharma
Gemin X Biotechnologies
Gemin X Pharmaceuticals
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
GenPat77
Genta
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Got-a-Gene
GP Pharm
Green Cross
Gryphon Therapeutics
GTx
Harbor BioSciences
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Ivy Medical Chemicals
Johnson & Johnson
KAEL-GemVax
Karo Bio
Karyon-CTT
Kinex
Kirax
Kissei
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Mannkind
Marillion Pharmaceuticals
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medivation
Menarini
Merck & Co
Merck KGaA
Merrion Pharmaceuticals
MethylGene
Micromet
Mojave Therapeutics
Molecular Insight
MolMed
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
Novartis
Novogen
Noxxon
NPS Pharmaceuticals
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Paladin Labs
Pantarhei Bioscience
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Progen
Progenics Pharmaceuticals
ProNAi Therapeutics
ProStrakan
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Salzburg Therapeutics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sapphire Therapeutics
Sarepta Therapeutics
SBIO
SciClone Pharmaceuticals
Seattle Genetics
SeleXel
Selvita
Semafore Pharmaceuticals
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Soligenix
Sophiris Bio
Spectrum Pharmaceuticals
SRI International
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Synageva BioPharma
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Tapestry Pharmaceuticals
Tau Therapeutics
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
Unigene
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaxon Biotech
Velacor Therapeutics
VentiRx Pharmaceuticals
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viralytics
ViroTarg
VM Discovery
XBiotech
Xencor
Xerion
Xigen
Xoma
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zenotech
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
abiraterone acetate
ABT-510
adecatumumab
aderbasib
AEZS-108
afamelanotide
afatinib
aflibercept
alemtuzumab
ALT-801
alvocidib
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
angiopep+paclitaxel
APC-100
APR-246
ARC-100
atrasentan
AVX-701
bafetinib
belinostat
bevacizumab
bexarotene
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
BP-GMAX-CD1
brentuximab vedotin
buserelin
Cabozantinib
carlumab
CBP-501
cediranib
celecoxib
cetuximab
cixutumumab
cladribine
corticorelin acetate
custirsen
danusertib
dasatinib
DCVax-prostate
degarelix
denileukin diftitox
denosumab
deslorelin
DI-17E6
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dutasteride
E-75
elliptinium acetate
emepepimut-S
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
FPI-01
fulvestrant
galiximab
gataparsen
GDC-0980
gefitinib
goserelin
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HBP-347
HE-3235
Her-2/Neu peptides
histrelin
ibritumomab tiuxetan
idronoxil
imatinib mesilate
imMucin
inecalcitol
inotuzumab ozogamicin
INSM-18
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
interleukins
intetumumab
ipilimumab
IPP-204106
irinotecan hydrochloride
irosustat
ISA-P53-01
ispinesib mesylate
kahalalide F
KX2-391
lanreotide
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
LOR-2040
LOR-2501
LY-2275796
MCS-110
MDV-3100
MDX-1379
mitoxantrone
MLN-8237
Nab-docetaxel
nadroparin
NAFB001
netupitant
nilutamide
nimotuzumab
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
OGX-427
olaparib
olaratumab
orteronel
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
pasireotide
pasireotide LAR
perifosine
pertuzumab
pixantrone
plitidepsin
PLX-3397
polyclonal antibody stimulator
pralatrexate
ProstAtak
PROSTVAC
PRX-302
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
ramucirumab
razoxane
Reditux
retaspimycin
rhIFN-alpha
ridaforolimus
rilotumumab
rindopepimut
rituximab
romidepsin
romurtide
ruxolitinib
sagopilone
sargramostim
SB-939
siltuximab
sipuleucel-T
sobuzoxane
sorafenib tosylate
sotatercept
Survivac
TAK-448
tandutinib
tasquinimod
temsirolimus
Tenarad
teniposide
thymalfasin
TM-30339
TOK-001
toremifene citrate
TRC-105
tremelimumab
trilostane
triptorelin
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
vapreotide, immediate-release
vitespen
VX-001
YM-155
zanolimumab
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lymphoma, Prostate Cancer and Peptides.
    To find out more about Triple Analysis: Lymphoma, Prostate Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lymphoma, Prostate Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More


Triple Analysis: Colorectal Cancer, Leukemia and Peptides
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Prostate Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Peptides. Learn More


Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More